Shutdown
Jul 2026Endpoints reported the company appears to be winding down after an employee LinkedIn post; no formal shutdown filing was located.
SourceArpeggio Bio develops drugs targeting transcription factors using AI…
Company research
Public company, workplace, funding, and market signals
Overview
Arpeggio Bio is a Boulder-based preclinical biotech developing transcriptomics-driven therapies and drug-discovery tools to tackle undruggable transcription factors, especially in cancer, chronic kidney disease, and neurodegeneration. Public reporting in July 2026 suggests the company may be winding down.
Primary product
A proprietary transcriptomics / chemotranscriptomics drug-discovery platform (GRETA)
Founded
2017
Headquarters
Boulder, Colorado, United States
Team size
10-20
Work style
Onsite
Industry
Biotechnology
Sub-industry
Preclinical therapeutics / transcriptomics-enabled drug discovery
Offices
Boulder, Colorado, United States
Business model
Preclinical therapeutics development
Platform-enabled drug-discovery collaborations
Research partnership / service contracting
Funding
Stage
Series B
Total raised
$57.5M
Latest round
Series B / latest offering · Nov 2025
Latest amount
$20M
People & investors
Leadership
CEO & co-founder
COO & co-founder
CTO / co-founder / Head of Discovery Biology
Chief Scientific Officer
Andy Ren
Head of Drug Discovery
Work & culture
Mission-driven and multidisciplinary, with an emphasis on courage, intellectual curiosity, respect, care, openness, and collaboration across biology, chemistry, engineering, and business.
Work style
Onsite
Product & market
Pricing
B2B partnerships / platform collaborations; pricing not publicly disclosed
Differentiators
- —Targets undruggable transcription factors
- —Combines proprietary biological assays with machine learning
- —Uses transcriptomics to infer mechanism of action
- —Large proprietary chemotranscriptome dataset
- —Automated robotics lab for screening
- —Focuses on network biology rather than single-target binding
Technology
Functional genomics
High-throughput transcriptomics / nascent RNA sequencing
Machine learning
Laboratory automation / robotics
Biological assays for mechanism-of-action screening
CRISPR-enabled disease modeling
Biophysical assays
Molecular glue degrader discovery
Customers
40+ pharmaceutical company partners (reported)
Forma Therapeutics (collaboration)
Intrinsic Medicine (partnership)
Competitors
Enveda Biosciences
Aro Biotherapeutics
Anthos Therapeutics
Schrödinger
Moderna
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
419
Traffic estimate as of Jun 2026
Signals & risks
Latest news
Endpoints News · Jul 2026
Endpoints reported Arpeggio appears to be winding down, citing an employee LinkedIn post and noting the biotech had raised more than $60M according to Joey Azofeifa's LinkedIn bio.
BizWest · Nov 2025
BizWest reported Arpeggio had raised about two-thirds of its latest investment offering, referencing the Boulder-based biotech's SEC filing.
AACR / Cancer Research abstract · Apr 2025
AACR abstract described ARP-4922, an NRF2 molecular glue degrader with strong activity in NRF2/KEAP1-mutant cancer models, including lung cancer xenografts.
Slone Partners · May 2024
Slone Partners announced Kevin Eastwood's placement as Chief Business Officer at Arpeggio Biosciences.
Business Wire · Sep 2022
Arpeggio closed a $17M Series A led by Builders VC, with support from seed investors and new participants including Tencent, ATEM Capital, Formic Ventures, Tau Ventures, and others.
Jobs and careers at Arpeggio Bio
0 jobs at Arpeggio Bio
No open positions
Check back later for new openings